Drug Detail

Information about CS1001 + Regorafenib

Generic Name
IND
CS1001 + Regorafenib
Brand Name (US)
Manufacturer
CStone Pharmaceuticals
Drug Type
Trial Combination
Delivery
Intravenous + Oral
Approval Status
CS1001 is in Phase 3, Regorafenib is approved for GIST
Indications
Overall Strategy
tumor signal path + immune system
Strategy
Immune checkpoint inhibitor enhanced by TKI
Drug Category
PD-L1 inhibitor + TKI